-
公开(公告)号:LT2464337T
公开(公告)日:2019-05-10
申请号:LT10708442
申请日:2010-02-18
Applicant: VERTEX PHARMA
-
公开(公告)号:LT2328618T
公开(公告)日:2018-03-26
申请号:LT09789125
申请日:2009-08-13
Applicant: VERTEX PHARMA
-
83.
公开(公告)号:HRP20170682T1
公开(公告)日:2017-07-14
申请号:HRP20170682
申请日:2017-05-05
Applicant: VERTEX PHARMA
Inventor: HURTER PATRICIA , GONG YUCHUAN , YOUNG CHRISTOPHER R , CONNELLY PATRICK , ROWE WILLIAM , COSTACHE ADRIANA , KRAWIEC MARIUSZ , FENG YUSHI , TRUDEAU MARTIN
IPC: C07D215/56 , A61K31/445
-
84.
公开(公告)号:DK1993360T3
公开(公告)日:2017-05-22
申请号:DK06848237
申请日:2006-12-28
Applicant: VERTEX PHARMA
Inventor: HURTER PATRICIA , GONG YUCHUAN , YOUNG CHRISTOPHER R , CONNELLY PATRICK , ROWE WILLIAM , COSTACHE ADRIANA , KRAWIEC MARIUSZ , FENG YUSHI , TRUDEAU MARTIN
IPC: C07D215/56 , A61K31/445
-
公开(公告)号:EA021706B1
公开(公告)日:2015-08-31
申请号:EA201170330
申请日:2009-08-13
Applicant: VERTEX PHARMA
Inventor: ROWE WILLIAM , HURTER PATRICIA , YOUNG CHRISTOPHER , DINEHART KIRK , VERWIJS MARINUS JACOBUS , OVERHOFF KIRK , GROOTENHUIS PETER D J , BOTFIELD MARTYN , GROSSI ALFREDO
IPC: A61K47/32
Abstract: Изобретениеотноситсяк областифармацевтики, аименнок таблетке, содержащейтвердуюдисперсию N-[2,4-бис-(1,1-диметилэтил)-5-гидроксифенил]-1,4-дигидро-4-оксохинолин-3-карбоксамидаи способуеевведения. Заявленнаятаблеткахарактеризуетсяхорошейрастворимостьюи высокойстабильностью.
-
公开(公告)号:NZ597823A
公开(公告)日:2014-05-30
申请号:NZ59782310
申请日:2010-02-18
Applicant: VERTEX PHARMA
Inventor: ROWE WILLIAM , HURTER PATRICIA , YOUNG CHRISTOPHER R , DINEHART KIRK , VERWIJS MARINUS JACOBUS , OVERHOFF KIRK , GROOTENHUIS PETER D J , BOTFIELD MARTYN , GROSSI ALFREDO , ZLOKARNIK GREGOR , VAN GOOR FREDRICK F
Abstract: 597823 Disclosed herein are pharmaceutical compositions comprising a solid dispersion of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (compound 1) for use treating or lessening the severity of cystic fibrosis in a patient, and method of manufacturing said compositions. In a preferred embodiment the patient possesses a cystic fibrosis transmembrane receptor (CFTR) with a &Dgr;F508 mutation or G551D mutation on both alleles.
-
87.
公开(公告)号:AU2006332726B2
公开(公告)日:2012-12-13
申请号:AU2006332726
申请日:2006-12-28
Applicant: VERTEX PHARMA
Inventor: HURTER PATRICIA
IPC: A61K31/445
Abstract: The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.
-
公开(公告)号:HK1161140A1
公开(公告)日:2012-08-24
申请号:HK12102076
申请日:2012-02-29
Applicant: VERTEX PHARMA
Inventor: ROWE WILLIAM , HURTER PATRICIA , YOUNG CHRISTOPHER , DINEHART KIRK , VERWIJS MARINUS JACOBUS , OVERHOFF KIRK , GROOTENHUIS PETER D J , BOTFIELD MARTYN , GROSSI ALFREDO
IPC: A61K20060101
Abstract: The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.
-
公开(公告)号:CA2769695A1
公开(公告)日:2011-02-17
申请号:CA2769695
申请日:2010-02-18
Applicant: VERTEX PHARMA
Inventor: ROWE WILLIAM , HURTER PATRICIA , YOUNG CHRISTOPHER R , DINEHART KIRK , OVERHOFF KIRK , GROOTENHUIS PETER D J , BOTFIELD MARTYN , GROSSI ALFREDO , ZLOKARNIK GREGOR , VAN GOOR FREDRICK F , VERWIJS MARINUS JACOBUS
Abstract: The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis( 1, 1 -dimethylethyl)-5-hydroxyphenyl]- 1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.
-
公开(公告)号:ES2351947T3
公开(公告)日:2011-02-14
申请号:ES07795477
申请日:2007-05-30
Applicant: VERTEX PHARMA
Inventor: HURTER PATRICIA , KADIYALA IRINA , LIN WU
IPC: A61K9/16 , A61K9/20 , A61K31/401
Abstract: Un procedimiento de formulación del compuesto de Fórmula (I), **(Ver fórmula)**que comprende: granular el compuesto de Fórmula (I) en presencia de un disolvente orgánico; en el que (a) la estabilidad del compuesto de Fórmula (I) en el disolvente orgánico es tal que el disolvente no provoca la degradación de más del 5% del compuesto de Fórmula (I) 10 durante 24 horas a, o por debajo, de la temperatura ambiente, (b) el material granulado en húmedo tiene un valor de disolución intrínseca menor que aproximadamente 0,15 mg/min/cm2, y (c) el material granulado en húmedo tiene una densidad entre aproximadamente 0,20 g/cm3 y aproximadamente 0,90 g/cm3.
-
-
-
-
-
-
-
-
-